160 results
8-K
EX-99.1
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
designation to pamrevlumab for the treatment of patients with LAPC. Pamrevlumab has demonstrated a safety and tolerability profile that has supported … Network. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential success
8-K
EX-99.1
q9fid0aork3p27
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
EX-99.1
s4d2nr2
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
sd2lvjk
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
elbx970rwyo 9byovi62
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
2du2 lxxge3zw
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
uvj3rkn7ydszw4yf9
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
7x2zdmd1p 37yjmh8z
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
moy il44o5hd
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm